Anti-excitotoxic sustained release intraocular implants and related methods

Details for Australian Patent Application No. 2005240081 (hide)

Owner Allergan, Inc.

Inventors Hughes, Patrick M.; Sugimoto, Hiroshi; Blanda, Wendy M.; Spada, Lon T.; Chang, James N.

Agent Davies Collison Cave

Pub. Number AU-B-2005240081

PCT Pub. Number WO2005/107718

Priority 10/837,142 30.04.04 US

Filing date 28 April 2005

Wipo publication date 17 November 2005

Acceptance publication date 24 June 2010

International Classifications

A61K 31/13 (2006.01) - Amines, e.g. amantadine

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

Event Publications

16 November 2006 PCT application entered the National Phase

  PCT publication WO2005/107718 Priority application(s): WO2005/107718

24 June 2010 Application Accepted

  Published as AU-B-2005240081

21 October 2010 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 28 Sep 2010. Address for service in Australia - Davies Collison Cave 255 Elizabeth Street Sydney NSW 2000

10 February 2011 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 28 Sep 2010

17 February 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005240082-Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients

2005240078-Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing